Glenmark Pharmaceuticals Launches Tevimbra: A Milestone in Cancer Treatment in India

Glenmark Pharmaceuticals announced the launch of their lung cancer treatment drug, Tevimbra, in India on Tuesday, subsequent to its approval by the Central Drugs Standard Control Organisation.

Tevimbra, developed by BeiGene, now operating under the name BeOne Medicines, signifies a pivotal entry into immune-oncology for Glenmark in India. This development is seen as a major step in diversifying Glenmark's innovative oncology offerings, according to a company regulatory filing.

The drug is approved for use in multiple leading global markets and is aimed at first-line treatment of locally advanced or metastatic non-small cell lung cancer combined with chemotherapy, as well as a second-line treatment for various advanced cancers, including oesophagal squamous cell carcinoma, said the company.

(With inputs from agencies.)